Our mission is focused on a new treatment for COVID-19 patients. We will take the Green-Tea therapy through clinical development. A pilot trial succeeded in 2020, see below. We are applying for an IND at the FDA and will need sites to test the therapy. Please join in! Our Italian colleagues invented this concept and conducted a pilot clinical trial in 10 swab-positive COVID-19 subjects in Italy during the COVID surge in the fall of 2020. All had symptoms of mild-to-moderate disease; the older 5 subjects had IL-6 levels of geometric mean 74 pg/ml, prognostic for severe disease. All subjects were cured of symptoms after a median of 9 days of treatment, range 7 - 15. 7/10 had negative swabs for SARS-Cov-2 at that time. Comparing these results to a population study of 4,430 COVID-19 swab positive patients in the next province (Mancuso et al. 2020) gave a probability of P < 0.003. (doi: 10.1136/bmjopen-2020-040380) Our pilot trial will duplicate their course of treatment. Their peer-reviewed paper is published here: https://www.mdpi.com/2673-8112/1/1/2/htm The severe form of COVID-19 is called SARS (Severe acute respiratory syndrome). It is virtually the same as ARDS (Acute Respiratory Distress Syndrome) which affects 200,000 patients in the US every year due to pneumonia and other causes. We will pursue the use of COVID-Tea therapy for ARDS once the pandemic lessens. We welcome collaboration and partnerships to bring this therapy to commercial success.